x

Posted 26 September, 2023

Morphic Holding, Inc. appointed new CEO

CEO Change detected for ticker Nasdaq:MORF in a 8-K filed on 26 September, 2023.


  Morphic Holding, Inc. ("Morphic" or "our") announces that Praveen Tipirneni, M.D., our Chief Executive Officer, experienced an unexpected medical event, is actively recovering, and is taking a temporary medical leave of absence. Effective immediately, our Chief Financial Officer and Chief Operating Officer, Marc Schegerin, M.D., and our President, Bruce N. Rogers, Ph.D., will assume day-to-day operational responsibilities in the near-term.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Morphic Holding, Inc.
Health Care/Life Sciences • Biotechnology
Morphic Holding, Inc. operates as a biopharmaceutical company, which engages in the research and development of oral small-molecule integrin therapeutics. It operates a Morphic integrin technology platform, MInT platform, to create a broad pipeline of programs across a variety of therapeutic areas. The company was founded by Timothy A. Springer in August 2014 and is headquartered in Waltham, MA.
Market Cap
$1.89B
View Company Details
Morphic Holding, Inc. by TradingView
Relevant filing section
Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officer; Compensatory Arrangements of Certain Officers.


Morphic Holding, Inc. ("Morphic" or "our") announces that Praveen Tipirneni, M.D., our Chief Executive Officer, experienced an unexpected medical event, is actively recovering, and is taking a temporary medical leave of absence. Effective immediately, our Chief Financial Officer and Chief Operating Officer, Marc Schegerin, M.D., and our President, Bruce N. Rogers, Ph.D., will assume day-to-day operational responsibilities in the near-term. Biographical information for Dr. Rogers and Dr. Schegerin may be found in Morphic's definitive proxy statement relating to its 2023 Annual Meeting of Shareholders filed with the U.S. Securities and Exchange Commission (the "Commission") on April 21, 2023.


A copy of a press release dated September 26, 2023 announcing this appointment has been included as Exhibit 99.1 to this Current Report on Form 8-K but shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.